Peptides for Immune System Support — The Complete Guide

T-Regulatory Maturation · Th1/Th17 Normalization · NK Cell Activation · Dendritic Cell Function

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymic tissue, where T-cell maturation occurs. The thymus involutes progressively from puberty onward — by age 40, thymic output of naive T-cells has fallen to a fraction of its youthful capacity. Thymosin Alpha-1 acts on dendritic cells and T-cell precursors to drive T-regulatory (Treg) and Th1 maturation — restoring the regulatory balance between Th1, Th2, and Th17 populations that thymic decline disrupts. Its Treg-promoting effect is most clinically relevant for conditions of immune over-activation: autoimmunity, chronic inflammatory disease, and the persistent low-grade systemic inflammation of aging. Its Th1 and NK cell activation effects are most relevant for immune under-function: impaired pathogen clearance, chronic viral infection, poor vaccine response, and cancer surveillance deficits. Published clinical data include trials in chronic hepatitis B and C, sepsis, HIV, influenza, lung cancer, and COVID-19.

NF-κB Suppression · 4,000+ Gene Modulation · Cytokine Network Regulation · Inflammaging Reversal

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring plasma tripeptide whose concentration declines from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. Published microarray analysis shows GHK-Cu modulates over 4,000 human genes, with the most consistent effect being downregulation of NF-κB-driven pro-inflammatory gene expression and upregulation of anti-inflammatory and tissue repair pathways. NF-κB is the master transcription factor of innate immune inflammatory activation — it governs TNF-alpha, IL-1beta, IL-6, IL-8, and the broader cytokine network that creates the chronic low-grade inflammation underlying aging-associated immune dysfunction. For immune health, GHK-Cu is the most appropriate systemic anti-inflammatory foundation compound.

Gut Epithelial Barrier Repair · GALT Immune Regulation · LPS Translocation Prevention · Intestinal NF-κB Suppression

Approximately 70% of the body's immune cells reside in the gut-associated lymphoid tissue (GALT). The gut epithelial barrier is the primary interface between the external antigenic environment and the systemic immune system. When disrupted — through dysbiosis, inflammation, or barrier failure — LPS, microbial antigens, and dietary proteins translocate into the systemic circulation, driving chronic immune activation that manifests as systemic inflammation. BPC-157's restoration of gut barrier integrity through VEGF-mediated angiogenesis and FAK-paxillin-driven tight junction repair removes the primary source of systemic immune activating stimulus. KPV's NF-κB suppression in intestinal epithelial and lamina propria immune cells directly reduces the intestinal inflammatory cytokine production driving both local and systemic immune dysregulation.

Mitochondrial ATP Restoration · Sirtuin Activation · Cardiolipin Protection · Immune Metabolic Reprogramming

Immune cells are among the most metabolically demanding cells in the body. Activated T-cells, NK cells, and macrophages undergo rapid proliferation and cytokine production that requires extraordinary mitochondrial ATP output. Immune cell mitochondrial dysfunction — driven by aging, oxidative stress, and NAD+ depletion — is a major mechanism of immune senescence. NAD+ is the central cofactor of mitochondrial oxidative phosphorylation and the substrate for sirtuins. NAD+ levels decline approximately 50% between ages 20 and 60. Elamiretide (SS-31) directly protects cardiolipin — the mitochondrial inner membrane phospholipid that scaffolds the electron transport chain complexes. Together, NAD+ addresses the cofactor depletion component while Elamiretide addresses the structural membrane integrity component — complementary and most effective in combination.

Telomerase Activation · T-Cell Progenitor Rejuvenation · Immune Repertoire Diversity · Pineal-Immune Crosstalk

Immune aging has both functional and structural dimensions. The structural dimension is telomere shortening in immune cell precursor populations: as T-cell and NK cell progenitors accumulate replicative divisions over a lifetime of immune challenges, their telomeres shorten, their replicative capacity declines, and the diversity of the immune repertoire narrows. Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) with the most extensively documented telomerase activation activity of any peptide in the VitalRx catalog. Its telomerase activation in lymphocyte populations extends the replicative lifespan of T-cell and NK cell progenitors, restoring the proliferative reserve and repertoire diversity that structural immune aging depletes. Published data show reduction in chromosomal aberrations, restoration of T-cell proliferative responses, and normalization of immune regulatory markers in aged subjects.

Primary Immune Compound

• Promotes T-regulatory cell maturation — restoring the immune tolerance machinery that thymic involution depletes
• Normalizes Th1/Th2/Th17 balance — addressing the regulatory dysregulation underlying autoimmunity and chronic inflammation
• Activates NK cells and enhances innate immune signaling — improving pathogen clearance and cancer surveillance
• Enhances dendritic cell function — improving antigen presentation and the quality of adaptive immune responses
• One of the most extensively clinically validated immune peptides: trials in chronic hepatitis, HIV, sepsis, influenza, and COVID-19
• Restores immune competence without broadly suppressing immune activity — the regulatory mechanism distinguishes it from immunosuppressive drugs

• Modulates over 4,000 genes — the most comprehensive anti-inflammatory gene modulation of any peptide in the catalog
• Suppresses NF-κB-driven pro-inflammatory cytokine production — reducing the chronic inflammatory tone that immune dysfunction maintains
• Restores the natural age-related decline in NF-κB negative regulation — addresses inflammatory aging at its upstream gene regulatory source
• VEGF upregulation supports vascularization and tissue repair in immune-inflamed tissue
• Decline in GHK-Cu plasma levels from age 20 to 60 is a documented mechanism of inflammaging
• Systemic compound — appropriate when chronic low-grade inflammation is a body-wide rather than organ-specific problem

• GHK-Cu: NF-κB suppression and 4,000+ gene anti-inflammatory modulation in a single injectable
• Epithalon: telomerase activation in immune cell precursors — extends T-cell and NK cell replicative lifespan
• Combination addresses both the inflammatory signaling layer (GHK-Cu) and the epigenetic structural aging layer (Epithalon)
• More cost-effective than purchasing GHK-Cu and Epithalon separately — single injection covers both mechanisms
• Appropriate for patients whose immune goals include both chronic inflammation reduction and immune aging reversal
• The longevity-oriented immune foundation compound — anti-inflammatory plus anti-aging in one vial

• Telomerase activation in lymphocyte populations — extends T-cell and NK cell progenitor replicative capacity
• Restores immune repertoire diversity by preserving the proliferative reserve of immune cell progenitors
• Reduces chromosomal aberrations in lymphocytes — documented in published aging studies
• Normalizes immune regulatory markers and T-cell proliferative responses in aged subjects
• Pineal regulatory effects normalize melatonin — melatonin has direct immunomodulatory activity
• Addresses the structural aging of the immune system that is upstream of functional immune deficits

• BPC-157: restores gut epithelial barrier integrity — removes the primary source of LPS-driven systemic immune activation
• KPV: suppresses NF-κB and pro-inflammatory cytokines in intestinal immune tissue — directly reduces GALT-driven systemic inflammation
• Oral delivery targets the gut lumen and mucosal surface directly — the highest-impact route for gut-immune barrier repair
• Addresses the gut permeability → LPS translocation → systemic immune activation cascade that drives chronic inflammaging
• The most appropriate mucosal immune intervention when gut-immune dysfunction is a contributing driver of systemic inflammation
• Well-tolerated — oral BPC-157 and KPV are among the best-tolerated compounds in the VitalRx catalog

• Restores mitochondrial NAD+ — the central cofactor of oxidative phosphorylation that immune cell activation depends on
• Activates sirtuins (SIRT1–7) — NAD+-dependent enzymes governing immune cell metabolic reprogramming and DNA repair
• SIRT1 activation specifically reduces NF-κB-driven pro-inflammatory cytokine production — complementary anti-inflammatory mechanism alongside GHK-Cu
• Improves NK cell and T-cell proliferative capacity — the energetic limiting factor in aged immune cells
• Supports the CD38/NAMPT NAD+ synthesis pathways that immune cell activation consumes rapidly
• The bioenergetic foundation of immune cell function — relevant for any immune protocol where cellular metabolic health is a concern

• Directly protects cardiolipin — the mitochondrial inner membrane phospholipid that anchors electron transport chain complexes
• Cardiolipin oxidation is the primary initiating event in immune cell mitochondrial dysfunction under chronic oxidative stress
• Targets the mitochondrial inner membrane preferentially — highest concentration where immune cell energetic failure originates
• Prevents cytochrome c release and downstream apoptotic immune cell death under inflammatory stress
• Restores ATP production efficiency in activated immune cells — the rate-limiting step in immune cell proliferation
• Complementary to NAD+: NAD+ addresses cofactor availability; Elamiretide addresses membrane structural integrity

Patients with chronically elevated inflammatory markers (CRP, IL-6, ESR, ferritin) in the absence of acute infection or injury — the most common immune pattern in adults over 45.

Patients with age-related immune decline — frequent infections, poor recovery, inadequate vaccine response, or documented immune senescence markers.

Patients with autoimmune conditions, allergic hyper-reactivity, or pathological immune activation against self — where the primary failure is insufficient regulatory suppression.

Patients recovering from prolonged viral illness, chemotherapy-induced immune suppression, sepsis, or post-infectious immune dysregulation.

Weeks 1–3

Early Anti-inflammatory and Mucosal Effects

GHK-Cu's NF-κB gene modulation begins with the first doses — patients with chronically elevated inflammatory markers often report reduced systemic inflammation symptoms (fatigue, joint discomfort, brain fog associated with elevated cytokines) within the first 2–3 weeks. BPC-157/KPV oral's gut-immune barrier repair begins acutely, with mucosal cytoprotective effects within the first week and progressive tight junction restoration over the following weeks.

Weeks 3–8

T-Cell Regulatory Normalization

Thymosin Alpha-1's T-regulatory cell promotion and Th1/Th17 normalization develops over this window. Patients with autoimmune conditions often report reduced flare frequency and severity within 4–8 weeks. Patients with immune senescence patterns typically begin noticing improved resilience within 4–6 weeks. NAD+'s bioenergetic effects on immune cell function are generally apparent within 2–4 weeks.

Months 2–6+

Epigenetic and Structural Immune Restoration

Epithalon's telomerase effects on immune progenitor populations are cumulative — the structural immune aging reversal requires multiple protocol cycles. Patients report the most significant immune aging improvements — better illness recovery, more robust immune responses — at 3–6 months of consistent protocol use. The most comprehensive immune protocols are typically maintained long-term with periodic provider reassessment.

Thymosin Alpha-1 — 3mg/mL, 5mL Injectable

T-regulatory cell maturation, Th1/Th17 normalization, NK cell activation. The foundation of most immune protocols.

GHK-Cu — 10mg/mL, 5mL Injectable

NF-κB suppression across 4,000+ genes. Systemic anti-inflammatory gene regulation.

GHK-Cu / Epithalon Blend — 5mL Injectable

Anti-inflammatory gene regulation + telomerase activation in one vial. The longevity-oriented immune foundation.

Epithalon — 2mg/mL, 5mL Injectable

Telomerase activation in immune progenitors. Structural immune aging reversal.

BPC-157 / KPV Oral — 500mcg + 500mcg, 20ct

Gut-immune barrier repair + intestinal NF-κB suppression. The mucosal immune layer.

NAD+ Injectable — 100mg/mL, 10mL

Mitochondrial NAD+ restoration and sirtuin activation. Immune cell bioenergetics.

Elamiretide (SS-31) — 15mg/mL, 5mL Injectable

Cardiolipin protection and mitochondrial inner membrane integrity under oxidative stress.

Identify Your Primary Immune Pattern

Is the primary issue chronic systemic inflammation — suggesting GHK-Cu as the foundational anti-inflammatory compound? Age-related immune senescence — suggesting Thymosin Alpha-1 with Epithalon? Autoimmune or immune over-activation — suggesting Thymosin Alpha-1's Treg promotion? Post-illness reconstitution — suggesting Thymosin Alpha-1 with NAD+ and Elamiretide? Or gut-driven systemic immune dysfunction — suggesting BPC-157/KPV as the mucosal layer?

Complete Your Async Provider Consultation

Answer a brief health intake describing your immune history, any relevant labs (CRP, CBC, autoimmune panels, vitamin D), current medications, and health goals. A licensed provider reviews your submission and issues your prescription when clinically appropriate. Consultation included with every order.

Receive Your Order

Your prescription is filled by Optimal Balance Pharmacy and shipped via FedEx Standard Overnight. Syringes and alcohol swabs included with all injectable orders.

Build the Full Protocol Over Time

Most immune protocols start with Thymosin Alpha-1 and GHK-Cu as the regulatory and anti-inflammatory foundation, then add epigenetic (Epithalon) and bioenergetic (NAD+, Elamiretide) layers as the protocol matures. The most comprehensive improvements develop over months of consistent use.